Release – V2X Awarded Position on $46 Million U.S. Air Force Contract Supporting B-52 Long Range Standoff Cruise Missile Program

V2X

Research News and Market Data on VVX

September 15, 2026

RESTON, Va., Sept. 15, 2026 /PRNewswire/ — V2X Inc. (NYSE: VVX) has been awarded a position on a $46 million delivery order on the Enterprise-Wide Agile Acquisition Contract Indefinite Delivery/Indefinite Quantity contract supporting the U.S. Air Force’s Carriage Equipment Production Effort for the Long Range Standoff (LRSO) cruise missile program.

The LRSO program is a critical modernization effort for the U.S. Air Force and an essential component of the nation’s strategic deterrent. Designed for deployment from the B-52 Stratofortress, the Long Range cruise missile will replace the currently fielded Air-Launched Cruise Missile, ensuring the Air Force’s long-range strike capability remains effective against evolving threats for decades to come.

Under the contract, V2X will provide carriage equipment production supporting the integration of the LRSO weapon system on the B-52, reinforcing the company’s role in advancing next-generation defense capabilities that strengthen mission readiness and national security.

“Supporting the modernization of the B-52 and our nation’s strategic deterrent is a responsibility we take seriously,” said Jeremy C. Wensinger, President and Chief Executive Officer of V2X. “This award reflects the trust our customer places in V2X to deliver high-quality solutions that enable mission success and support one of the Air Force’s highest modernization priorities.”

V2X delivers integrated mission solutions that enhance readiness and operational effectiveness across the air, land, sea, space, and cyber domains. The company’s expertise in engineering, manufacturing, sustainment, and mission support enables customers to address today’s most complex defense challenges while preparing for tomorrow’s evolving mission requirements.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
[email protected] 
719-637-5773

Media Contact
Angelica Spanos Deoudes
Senior Director, Marketing and Communications
[email protected] 
571-338-5195

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-awarded-position-on-46-million-us-air-force-contract-supporting-b-52-long-range-standoff-cruise-missile-program-302878543.html

SOURCE V2X, Inc.

GeoVax Labs (GOVX) – GEO-MVA Phase 3 Trial Moves Forward With Laboratory Testing Agreement For Patient Samples


Tuesday, September 15, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Agreement With CEPI Lab Network Establishes Standardized Sample Testing. GeoVax announced an agreement with CEPI (Coalition for Epidemic Preparedness Innovations) to test patient samples from its Phase 3 GEO-MVA study through the CEPI Centralized Laboratory Network. CEPI is an internationally recognized laboratory network that uses standardized assays and laboratory methods. We see this as an important development that can provide reliable results for both regulatory approval and comparison with other therapeutics.

An Important Step For The GEO-MVA Trial. GeoVax reiterated its plan to begin its GEO-MVA immunobridging study in Mpox/smallpox in 4Q26. The trial is expected to enroll about 500 patients, with results expected in mid-2027. The EMA (European Medicines Agency) has given Scientific Advice stating that a single immune bridging study showing that an immune response elicited by the GEO-MVA vaccine is non-inferior to the approved vaccine would be sufficient to apply for approval from the European Union.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

10-Year Treasury Yield Tops 5% as Bond Market Reshapes the Investment Landscape

The U.S. bond market is sending one of its clearest signals in years that borrowing costs may remain elevated for longer than investors had hoped.

The benchmark 10-year Treasury yield climbed above 5%, while the 30-year Treasury yield pushed to its highest level since 2007, extending a sharp selloff in government bonds as investors contend with persistent inflation, rising energy prices, elevated federal borrowing and expectations for tighter Federal Reserve policy.

For investors, 5% is more than a psychological milestone. Treasury yields help establish the cost of money throughout the U.S. economy, influencing everything from mortgages and corporate borrowing to equity valuations and merger financing. At the same time, government bonds yielding around 5% provide investors with a considerably more competitive alternative to stocks than they had for much of the post-financial-crisis era. The result is a financial environment in which the bond market is again playing a central role in determining where capital flows and what investors are willing to pay for risk.

Why Treasury Yields Are Moving Higher

Several forces are pushing long-term rates in the same direction. Inflation remains one of the most immediate concerns. Consumer prices were 3.4% higher in August than a year earlier, with energy becoming an increasingly important source of pressure. Rising oil prices tied to continuing Middle East instability have strengthened concerns that inflation could remain above the Federal Reserve’s 2% target for longer, potentially limiting policymakers’ ability to ease financial conditions.

Energy is particularly important because its impact extends beyond the gasoline pump. Higher crude prices can raise transportation, freight, manufacturing and airline costs, creating the possibility that an initially concentrated energy shock eventually spreads into other parts of the economy. That concern has contributed to expectations that the Federal Reserve may need to maintain — or potentially increase — restrictive policy.

Government borrowing is another important part of the equation. Investors continue to focus on the size of federal deficits and the large amount of Treasury debt that must be issued to finance them. As bond supply increases, buyers may demand higher yields to absorb the additional issuance, particularly when uncertainty around inflation and future interest rates is already elevated. That dynamic contributes to what economists call the term premium — the additional compensation investors demand for holding longer-term bonds when future inflation, interest rates and fiscal conditions are uncertain.

Why 5% Is Historically Significant

A 5% Treasury yield is not extraordinary when viewed across several decades, but it represents a dramatic departure from the environment investors became accustomed to after the 2008 financial crisis. The 10-year Treasury regularly traded around or above 5% during portions of 2006 and 2007. After the financial crisis, however, weak growth, low inflation, quantitative easing and eventually the pandemic helped push long-term borrowing costs dramatically lower. In late 2021, the 10-year Treasury yield averaged less than 1.5%.

The subsequent reversal has been substantial. The 10-year approached 5% during the 2023 bond-market selloff before retreating, while the latest move has pushed it through that threshold again. The 30-year Treasury has followed a similar trajectory and is now trading at levels not seen since before the financial crisis. That shift matters because low rates provided a structural tailwind for financial assets for much of the past 15 years. Investors could borrow cheaply, companies could refinance debt at attractive rates and low bond yields made equities comparatively more appealing. A sustained return to 5% long-term Treasury yields would represent a meaningfully different investment backdrop.

Why Higher Yields Matter for Stocks

The connection between bonds and equities begins with valuation. Investors value companies partly by estimating the present value of future earnings and cash flows. When the risk-free rate rises, those future earnings are discounted more heavily, reducing the amount investors may be willing to pay for them today. The effect can be particularly pronounced for companies whose valuations depend heavily on profits expected many years into the future.

That is one reason technology and other high-growth stocks can be especially sensitive to sharp increases in long-term interest rates. A company trading at a high earnings multiple must now compete for investor capital against a Treasury security yielding approximately 5% with substantially less risk. That does not automatically make stocks unattractive. Equities offer earnings growth and capital appreciation that fixed-income securities do not. But a 5% government yield raises the return investors can earn without assuming corporate or equity-market risk, effectively increasing the hurdle rate stocks must clear. Higher yields can therefore pressure valuation multiples even when company fundamentals remain healthy.

The Pressure Reaches the Real Economy

The effects extend well beyond Wall Street. Mortgage rates tend to move with long-term Treasury yields, although the relationship is not one-for-one. Persistently elevated Treasury yields can therefore keep mortgage rates high, adding further pressure to a housing market already struggling with affordability. Higher monthly payments reduce purchasing power, while homeowners who secured mortgages at much lower rates have less incentive to move, limiting transaction activity and housing inventory turnover.

Businesses face similar challenges. Corporate bonds, bank loans and other forms of credit must compete with Treasury securities for investor capital, meaning higher government yields typically translate into more expensive financing for companies as well. That can become particularly important when older debt matures. Companies that borrowed at 3% or 4% several years ago may now need to refinance at considerably higher rates, increasing interest expense and potentially reducing funds available for investment, hiring or acquisitions. Smaller and middle-market companies can be especially sensitive because they often have fewer financing options and less balance-sheet flexibility than the largest public companies.

Higher Rates Can Change the M&A Equation

The same dynamics can influence merger and acquisition activity. Acquisitions frequently rely on debt financing, and higher interest rates can reduce the price a buyer can economically justify paying for a target. Private equity transactions are particularly rate-sensitive because leveraged buyouts typically depend on substantial borrowing to generate returns.

Higher financing costs do not mean M&A disappears. Strategic buyers with significant cash reserves can remain active, and valuation resets can create attractive acquisition opportunities for well-capitalized companies. Companies facing refinancing or capital constraints may also become more willing sellers. In that sense, a higher-rate environment can reshape dealmaking rather than simply stop it. Buyers with strong balance sheets may find themselves in a more advantageous position as financing becomes more difficult for competitors.

Could Higher Yields Create Opportunities in Small Caps?

Small-cap stocks are often viewed as particularly vulnerable to rising rates, and there are legitimate reasons for that concern. Smaller companies tend to rely more heavily on external financing, generally have higher borrowing costs than large corporations and often carry a greater proportion of floating-rate or shorter-duration debt. But the effect is not uniform across the small-cap universe.

Financials, industrials and healthcare represent significant portions of major small-cap indexes, and some companies within those sectors can benefit from the economic conditions accompanying higher yields. Regional and community banks are one example. If longer-term yields rise while short-term rates remain relatively contained, a steeper yield curve can improve the spread between what banks pay for funding and what they earn on loans. Smaller industrial companies can also benefit if higher yields partly reflect continued economic strength rather than simply deteriorating inflation. Many small-cap businesses are more domestically focused than the largest multinational corporations, leaving them relatively exposed to U.S. capital spending, infrastructure investment and economic activity.

That distinction is important. A 5% Treasury yield caused primarily by accelerating inflation and tightening credit would be much more problematic for small caps than a 5% yield accompanied by healthy growth, strong corporate earnings and functioning credit markets. Higher rates may also create greater separation between individual companies. Businesses with excessive debt, weak cash flow or repeated financing needs may struggle, while companies with healthy balance sheets, strong free cash flow and limited refinancing requirements could become more attractive by comparison. For small-cap investors, that could make company selection increasingly important. A higher-rate environment may be less forgiving, but it can also create valuation differences and opportunities that were harder to find when cheap money lifted a much broader range of companies.

The Fed Faces a Difficult Policy Balance

The Federal Reserve now faces an unusually complicated setup. Ordinarily, weakening financial conditions and pressure in rate-sensitive areas such as housing would strengthen the argument for easier monetary policy. But inflation remains above target, while higher energy costs threaten to place renewed upward pressure on consumer prices. That leaves policymakers balancing two competing risks: allowing inflation expectations to become entrenched or tightening financial conditions enough to weaken the economy unnecessarily.

There is another complication. The Fed directly controls short-term interest rates, but long-term Treasury yields are determined by the market. Even if policymakers eventually begin lowering short-term rates, the 10-year and 30-year yields could remain elevated if investors continue demanding higher compensation for inflation risk, government borrowing or fiscal uncertainty. In other words, a future Fed rate cut would not necessarily guarantee an immediate return to cheap long-term borrowing.

What Investors Should Watch Next

The immediate focus is on Federal Reserve policy, but the Treasury market itself may prove equally important. Investors will be watching whether oil prices and inflation remain elevated, how Treasury markets absorb continued government debt issuance and whether higher financing costs begin materially slowing economic growth. Credit spreads will also be worth monitoring, particularly for smaller and lower-rated companies, because a significant widening would indicate that investors are becoming more concerned about corporate default risk in addition to higher underlying interest rates.

The reason behind the rise in yields may ultimately matter as much as the level itself. Elevated yields driven by resilient economic growth and strong nominal activity can coexist with healthy corporate earnings and opportunities in cyclical sectors. A sustained increase driven by worsening inflation expectations or fiscal concerns would create a more challenging environment. That nuance is especially important for equity investors. Higher yields are clearly a tightening of financial conditions, but they do not automatically imply negative outcomes for every company or sector. Banks benefiting from improved lending economics, businesses with strong balance sheets and domestically oriented companies supported by continued economic activity may still perform well.

For investors, the question is therefore not simply whether Treasury yields are high, but why they are high, how long they remain elevated and which companies are best positioned to operate in that environment. The last time long-term Treasury yields consistently traded near these levels, the financial system looked very different. Whether today’s move proves temporary or signals a more durable higher-rate regime remains uncertain.

What is already clear is that the bond market can no longer be treated as background noise. With the benchmark 10-year Treasury yield around 5%, the cost of money is once again one of the most important forces shaping valuations, financing decisions and investment opportunities across the market.

Lindblad Expeditions Expands Experiential Travel Portfolio With White Desert and Echo Charlie Acquisition

Lindblad Expeditions Holdings (NASDAQ: LIND) is making the largest acquisition in its history, acquiring a 60% majority stake in White Desert Antarctica and Echo Charlie for approximately $61 million in cash, plus roughly $6 million for cash on the balance sheet and customary adjustments.

The transaction gives Lindblad a stronger position in high-end experiential travel by adding a luxury Antarctic operator and a new aviation-focused adventure brand to a portfolio that already spans expedition cruising, wildlife travel, cycling, cultural trips and other specialty experiences. Lindblad said White Desert and Echo Charlie will continue to operate as stand-alone brands while gaining access to the company’s broader distribution, resources and operating platform.

For investors, the deal is notable not only because of its size relative to Lindblad’s acquisition history, but because it extends the company beyond its traditional marine-expedition roots and further into premium land- and air-based travel.

Adding Luxury Antarctica and Aviation to the Portfolio

White Desert was founded in 2005 by polar explorer Patrick Woodhead and specializes in flying guests directly into the Antarctic interior.

Its itineraries include trips to the Geographic South Pole and visits to an Emperor penguin colony of more than 20,000 birds, combining access to remote areas with luxury accommodations and extensive logistics. The company employs more than 150 people from 18 nationalities and has built its brand around aviation, safety and small-scale high-end travel.

Echo Charlie takes the aviation concept outside Antarctica. The newer brand operates luxury adventure journeys aboard a restored DC-3 carrying just 12 guests, with itineraries designed around remote destinations including Colombia, Patagonia, the Faroe Islands and Greenland. Lindblad sees the platform as a way to broaden its reach into places that are difficult to access through conventional commercial travel.

Woodhead will remain chairman of White Desert and CEO of Echo Charlie and will also join Lindblad as Strategic Innovation Advisor. That founder-led continuity appears deliberate. Lindblad has used a similar model in prior acquisitions, allowing specialty brands to retain their identity while plugging into the parent company’s broader infrastructure and customer base.

Lindblad Continues Building a Multi-Brand Travel Platform

The transaction fits a strategy Lindblad has been pursuing for years: expanding from expedition cruising into a broader collection of differentiated travel businesses.

The company now describes itself as operating across air, land and sea, with brands including National Geographic-Lindblad Expeditions, Natural Habitat Adventures, Off the Beaten Path, DuVine Cycling + Adventure Co., Classic Journeys and Wineland-Thomson Adventures, along with White Desert and Echo Charlie.

Natural Habitat Adventures, for example, expanded Lindblad into land-based wildlife and ecotourism, including polar bear expeditions in Canada, Alaskan wildlife trips and African safaris. That acquisition helped establish the template for adding specialty experiential brands rather than simply expanding the company’s cruise fleet.

White Desert and Echo Charlie push that strategy further. Rather than purchasing additional ship capacity, Lindblad is adding specialized aviation capabilities and premium experiences that potentially allow it to serve existing customers in different ways. That could be important because affluent adventure travelers often purchase multiple types of trips rather than remaining loyal to a single travel format.

The Deal Comes as Lindblad’s Core Business Is Growing

Lindblad is making the acquisition from a position of improving operating momentum.

In the second quarter of 2026, total revenue increased 19% to $199.2 million, while adjusted EBITDA rose 31% to $32.5 million. Occupancy increased to 91% from 86%, and the Lindblad segment posted a record second-quarter net yield of $1,294 per available guest night.

The company also raised its full-year guidance alongside the acquisition announcement. Lindblad now expects 2026 tour revenue of $850 million to $880 million and adjusted EBITDA of $140 million to $148 million, reflecting both the additions of White Desert and Echo Charlie and continued strength in the existing business.

That backdrop matters because acquisitions are generally easier to absorb when the underlying platform is already growing. Lindblad is not relying solely on M&A to generate momentum; its existing operations have also been posting higher revenue, occupancy and yields.

Why Experiential Travel Is Attracting Investment

The broader industry backdrop helps explain the strategic appeal.

Adventure and experiential travel have moved well beyond a niche segment. The Adventure Travel Trade Association estimates the global outbound adventure-travel market at approximately $1.16 trillion, with 67% of international travelers classified as “open to adventure.” The organization says travelers increasingly prioritize new experiences, cultural connection, off-the-beaten-path destinations and sustainability.

Its 2026 industry survey also found that nearly 60% of adventure-tour operators reported revenue growth in 2025, while 61% expect higher net profits in 2026. Operators cited new customers, geographic expansion and product diversification as important drivers.

The luxury end of the market is particularly relevant to Lindblad’s acquisition. Virtuoso’s 2026 Luxe Report ranked Antarctica as the top adventure destination and one of the leading destinations on the rise. Expedition cruising was also among the year’s leading travel trends, while 45% of surveyed advisors reported increasing demand for “ultraluxe” travel such as highly private and hyper-personalized experiences.

Those trends line up closely with what White Desert and Echo Charlie offer: small guest counts, difficult-to-reach destinations and experiences that are difficult to replicate independently.

Luxury Travel Has Been More Resilient

Another factor is the relative strength of affluent travelers.

The broader travel market has become increasingly bifurcated, with value-conscious consumers becoming more selective while wealthier travelers continue spending on premium experiences. Travel industry analysts have noted that luxury cruising and highly differentiated experiences have generally held up better than mass-market categories in 2026.

That has encouraged more travel companies to move upscale. Luxury hotel brands including Ritz-Carlton, Four Seasons and others have been expanding into yachts and cruises, while expedition operators increasingly combine remote destinations with hotel-level service. The common theme is that the product is becoming less about transportation and more about access, exclusivity and the experience itself.

White Desert fits directly into that trend.

A Different Kind of Scale

Unlike conventional cruise acquisitions, the strategic value here is not necessarily about adding thousands of passengers.

Echo Charlie carries just 12 travelers at a time, and White Desert is built around small-scale Antarctic access. That scarcity is part of the product.

For Lindblad, the opportunity is therefore to expand the value of each customer relationship rather than simply add capacity. A traveler who has already booked a National Geographic-Lindblad expedition or a Natural Habitat wildlife trip may also be a potential customer for a White Desert Antarctic journey or a highly specialized Echo Charlie itinerary.

That creates cross-selling opportunities across brands while preserving the exclusivity that supports premium pricing. It also diversifies Lindblad geographically and operationally. The company remains heavily associated with ships and expedition cruising, but the portfolio increasingly includes land and aviation experiences that do not depend on adding cruise capacity.

Travelzoo Offers Another View Into Experiential Travel Demand

Investors interested in the broader experiential travel theme can also look at Travelzoo (NASDAQ: TZOO), which is covered by Noble Capital Markets.

Travelzoo operates a global travel and experiences platform that connects its members with curated travel, entertainment and lifestyle offers. While its business model differs significantly from Lindblad’s direct ownership of expedition brands, both companies participate in a travel market increasingly shaped by consumers seeking distinctive experiences rather than simply transportation and lodging.

Noble Capital Markets provides research coverage of Travelzoo, giving Channelchek readers another publicly traded company through which to follow trends in premium and experiential travel.

Building a Broader Experiential Travel Company

The White Desert and Echo Charlie acquisition represents more than an expansion of Lindblad’s Antarctica business.

It advances the company’s transformation from a primarily expedition-cruise operator into a diversified experiential travel platform spanning ships, wildlife expeditions, cycling tours, cultural travel and now specialized aviation.

The immediate financial contribution remains relatively modest compared with Lindblad’s overall revenue base, but strategically the transaction opens another avenue for selling premium experiences to a customer base already inclined toward remote and adventure-oriented travel.

With adventure tourism becoming increasingly mainstream while affluent travelers continue prioritizing highly personalized experiences, Lindblad is betting that the next stage of growth will come not simply from carrying more passengers, but from offering more ways to reach places most travelers cannot easily reach on their own.

Release – Conduent Names Narayanan Sundaresan Chief Information and Technology Officer

Research News and Market Data on CNDT

September 14, 2026

Corporate

Technology leader brings more than 28 years of experience driving enterprise transformation, AI innovation and technology strategy for large, regulated organizations.

Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced the appointment of Narayanan Sundaresan as Chief Information and Technology Officer , effective September 14, 2026.

Narayanan Sundaresan

Narayanan Sundaresan

Sundaresan brings more than 28 years of experience leading enterprise technology organizations and digital transformation initiatives, with expertise driving AI-powered business transformation, modernizing enterprise platforms, advancing digital products, and strengthening cybersecurity and data governance.

At Conduent, Sundaresan will lead the Company’s global technology organization and strategy in support of transformation and growth. He will focus on accelerating the adoption of AI-powered capabilities across the enterprise while continuing to strengthen the secure, reliable and scalable technology foundation needed to support Conduent’s clients and operations. His leadership will help advance Conduent’s efforts to modernize operations, scale innovation and deliver measurable outcomes for clients.

“Narayanan joins Conduent at an important point in our transformation, and his experience will help us accelerate innovation, enhance client outcomes, and create greater value for our business,” said Harsha V. Agadi, Chief Executive Officer of Conduent. “I’m excited to welcome him to our leadership team and look forward to his impact as we turn our AI and technology strategy into measurable business results.”

“I’m honored to step into this role at a pivotal moment for Conduent,” said Narayanan Sundaresan, Chief Information and Technology Officer, Conduent. “My focus will be on two things that go hand in hand: accelerating the build-out of AI-powered capabilities across every part of the enterprise and scaling a technology infrastructure that is both secure and reliable enough to support that growth. AI only creates lasting value when it’s built on a foundation that clients and associates can trust.”

Prior to joining Conduent, Sundaresan served as Global Chief Information Officer and Senior Vice President, Digital Products & Technology at Strategic Education, where he led enterprise-wide AI work redesign and hyper-automation initiatives, technology harmonization across business units, and the development of global technology capabilities. He also previously held technology leadership positions at Capella Education Company, where he led digital technology initiatives, enterprise platforms and global technology delivery.

Sundaresan holds an MBA from the University of Minnesota Carlson School of Management and an M.S. in Software Engineering from the University of St. Thomas. He also completed the High Potential Leadership Program at Harvard Business School.

About Conduent
Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 48,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $80 billion in government payments annually, enabling approximately 2.0 billion customer service interactions annually, empowering millions of employees through HR services every year and processing over 14 million tolling transactions every day. Learn more at www.conduent.com .

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit https://x.com/Conduent , http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent .

Trademarks
Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contact:
Remy Kaul, Conduent, [email protected]

Investor Relations Contact:
Conduent, [email protected]

Release – GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial

GeoVax, Inc.

Research News and Market Data on GOVX

Independent Evaluation Supports GEO-MVA Pivotal Phase 3 Program

Advances GeoVax’s Strategy to Expand and Diversify MVA Vaccine Supply

ATLANTA, GA – September 14, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high consequence infectious diseases and solid tumor cancers, today announced that it has entered into a Memorandum of Agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) providing GeoVax access to clinical trial sample testing services through the CEPI Centralised Laboratory Network in support of its planned pivotal GEO-MVA Phase 3 immune-bridging study.

The agreement represents an important step in the continued development of GEO-MVA, GeoVax’s MVA-based vaccine candidate targeting mpox and smallpox. It provides access to independent laboratory testing using standardized assays and reporting procedures established through CEPI’s global laboratory infrastructure. CEPI’s network is the largest global group of laboratories dedicated to harmonizing the immunological assessment of vaccines in development against infectious diseases with epidemic and pandemic potential. With network scientists assessing clinical trial samples using the same methods and validated assays, the possibility of variability in trial readouts is minimized, helping researchers and regulators consistently evaluate vaccine performance in clinical trials. For GeoVax, the agreement also supports a broader strategic objective: building independent scientific evidence necessary to establish GEO-MVA as a potential additional source of MVA-based mpox vaccine supply at a time when outbreaks and preparedness requirements continue to demonstrate the importance of resilient, diversified vaccine capacity.

GeoVax expects to initiate its approximately 500-participant pivotal Phase 3 immune-bridging study in the fourth quarter of 2026, with results expected in mid-2027.

Recent global mpox outbreaks have underscored the risks of constrained vaccine supply and the importance of expanding MVA vaccine capacity. GeoVax believes sustainable preparedness will increasingly require not only adequate vaccine stockpiles, but also multiple qualified sources of supply and manufacturing capacity capable of serving different regions of the world.

“Independent evaluation is an important step toward building confidence in GEO-MVA among regulators, public-health organizations, governments and potential strategic partners,” said David Dodd, Chairman and Chief Executive Officer of GeoVax. “Our agreement with CEPI provides access to a highly respected global laboratory network capable of testing and characterizing immune responses associated with GEO-MVA.”

Dodd continued, “But the larger objective extends beyond development of another mpox vaccine. The global preparedness community needs resilient MVA supply. We believe that the data produced by CEPI’s network could pave the way for an additional qualified supply source of mpox vaccine supply if we are successful in testing and licensure, reducing dependence on a single manufacturing infrastructure and ultimately enabling production capacity that can be deployed closer to the populations it is intended to protect.”

Independent Evaluation Supporting an Expanded-Source Strategy

Under the agreement, clinical samples provided by GeoVax will be evaluated through the CEPI Centralised Laboratory Network using assays specific to orthopoxviruses, the family of viruses to which mpox and smallpox belong.

The independent nature of the testing is particularly important as GeoVax advances GEO-MVA toward its pivotal Phase 3 study. Results generated through CEPI’s laboratory network will provide independently generated and standardized immunological data that will inform GeoVax’s ongoing clinical development and future regulatory interactions.

“CEPI’s Centralised Laboratory Network was set up during the COVID-19 pandemic to help reduce clinical testing differences that can emerge from independent laboratory review to instead ensure easy access and alignment to key data that could support vaccine approvals” said Dr Amy Shurtleff, Director of Laboratory Research and Innovation Department at CEPI. “It has rapidly expanded since then, with vaccine developers around the world using the service to evaluate thousands of their samples produced during trials of promising vaccine candidates against other deadly pathogens, including mpox. Our new agreement with GeoVax enables the company to access validated, high-quality mpox testing tools that could fast-track its promising GEO-MVA mpox vaccine through development and give the world further options to fight this harmful, recurring disease.”

The agreement also provides a framework under which CEPI may share anonymized summaries of sample-testing results with the World Health Organization (WHO), Gavi, the Vaccine Alliance and others to further CEPI’s mission to transform the world’s response to epidemic and pandemic threats, including diseases like mpox.

GeoVax will cover the full testing costs associated with the research carried out by CEPI’s Centralised Laboratory Network. CEPI has not provided specific funding for the development of GEO-MVA.

 About GEO-MVA

GEO-MVA is GeoVax’s Modified Vaccinia Ankara (MVA)-based vaccine being developed for protection against mpox and smallpox. Following Scientific Advice from the European Medicines Agency (EMA), GeoVax is pursuing an immune-bridging development strategy that is intended to compare immune responses generated by GEO-MVA with those generated by the licensed MVA-BN comparator.

GeoVax is developing GEO-MVA to expand global access to MVA vaccine supply, scalable production capabilities, and a capital-efficient regulatory pathway. The Company believes GEO-MVA has the potential to become an important strategic preparedness asset by providing governments and international public health organizations with an additional, reliable source of MVA vaccine to support biosecurity and orthopoxvirus preparedness.

About CEPI and the Centralised Laboratory Network

CEPI is an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. Central to CEPI’s pandemic-beating plan is the ‘100 Days Mission’ to develop safe, effective and accessible vaccines against new threats in just 100 days. CEPI is seeking $2.5 billion to execute CEPI 3.0, its 2027-2031 strategy which will systematically reduce the likelihood, impact and cost of epidemics and pandemics by driving the 100 Days Mission towards an operational reality. Learn more at CEPI.net.

The Centralised Laboratory Network focuses on the assessment of vaccines against CEPI’s priority list of pathogens including Lassa, Nipah, mpox, MERS, Ebola, Chikungunya, Rift Valley fever and COVID-19.

Laboratory members also support testing of vaccines for other viral threats with epidemic or pandemic potential, like Marburg, and are on standby to help fast-track the assessment of vaccine candidates against a Disease X – a novel or as-of-yet unidentified pathogen. To date, the network has served over 60 vaccine developers to assess their vaccine candidates at all stages of developments, processing over 120,000 samples.

CEPI’s Centralised Laboratory Network members are listed here. Laboratories are selected to join the network based on their capacity, experience and scientific expertise in testing clinical samples using high-quality systems. Since its launch in 2020, CEPI has provided up to US $59 million to fund capability building and collect immunogenicity data in the network.

Data produced by members of the network is sent back to the vaccine developer. Neither CEPI nor the laboratory who assessed the samples owns the data.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the fourth quarter of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

 This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

 Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]

Release – Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

Cardiff Oncology, Inc. logo

Research News and Market Data on CRDF

September 14, 2026

PDF Version

Under the terms of the Amendment, all disputed issues are resolved

SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (NASDAQ: CRDF) (“Cardiff”) and Nerviano Medical Sciences S.r.l. (“NMS”) today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff’s lead PLK1 inhibitor drug candidate, and establishing an expanded collaborative framework to support onvansertib’s continued clinical development.

Cardiff and NMS have agreed to a full and mutual release of all claims asserted in the litigation pending in the U.S. District Court for the Southern District of California. Cardiff and NMS plan to jointly request dismissal of all claims with prejudice.

“This Amendment strengthens our long-term rights to onvansertib as a promising treatment for cancer, beginning with first-line RAS-mutated metastatic colorectal cancer,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “We are pleased to be entering into this agreement with NMS, which reflects our shared commitment to bringing onvansertib to patients with high unmet need.”

“We look forward to working with Cardiff to advance onvansertib into a global Phase 3 study in first-line RAS-mutated metastatic colorectal cancer and to bring this therapy to patients,” said Hugues Dolgos, PharmD, Chief Executive Officer of NMS Group S.r.l.

The Parties clarified and expanded on the royalty structure in the License Agreement. The agreement also includes development objectives related to Cardiff’s upcoming Phase 3 program, as well as rights for NMS to appoint a Board observer and join Cardiff’s Scientific Advisory Board.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated mCRC. In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 2 trial in second-line RAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab for advancement into a registrational trial in first-line patients with RAS-mutated mCRC.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

About NMS
NMS is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative oncology therapies. Building on a long-standing heritage in cancer biology and drug discovery, NMS combines a focused clinical-stage small-molecule portfolio with a differentiated ADC platform and an active discovery engine generating first-in-class oncology programs. NMS has operations in Italy, the United States, China and Hong Kong.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology’s expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third-party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology’s Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

For more information regarding Cardiff, please visit https://www.cardiffoncology.com.

Cardiff Investor Contact: 
Candice Masse 
Astr Partners 
[email protected] 

Cardiff Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]

For more information regarding NMS, please visit https://www.nervianoms.com/

NMS Media Contact: 
[email protected]

Resolution Minerals Ltd (RML) – Thoughts on the Golden Gate Drilling Program


Monday, September 14, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Golden Gate 2026 drilling program. Resolution has completed its planned 2026 Golden Gate drilling program at the Horse Heaven Project in Idaho, completing 42 diamond core holes totaling 12,236 meters. The program, the largest exploration campaign undertaken at Horse Heaven, was designed to define the scale and extent of both gold and tungsten mineralization across Golden Gate North and the recently established Golden Gate South discovery. Core logging is complete, and final samples are being sent to the laboratory for analysis, leaving assay results from 39 of the 42 holes as the principal near-term catalyst.

Early results suggest a potentially large gold system. Results from the first three 2026 holes extended gold mineralization at least 2,000 meters south of Golden Gate North and established Golden Gate South as a new discovery. The strongest 2026 result reported to date was 305.7 meters grading 0.64 g/t gold from surface in Hole HH-GG26-003C, while the 2025 program returned higher-grade intervals including 189.2 meters at 1.30 g/t gold and 253 meters at 1.5 g/t gold. Along with a broad gold-in-soil anomaly between the two areas, the results provide increasing evidence that Golden Gate may represent a considerably larger mineralized system than initially recognized.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AI Leaders Call for a Slowdown. Investors Are Asking What That Means for the AI Boom

For much of the artificial intelligence boom, the central question for investors has been how quickly the technology could advance.

This weekend, some of the industry’s most prominent executives raised a very different question: Should it advance this quickly at all?

Anthropic CEO Dario Amodei called for deliberately slowing the development of increasingly powerful frontier AI models, warning that capabilities are advancing faster than existing safety systems can keep up. OpenAI CEO Sam Altman, xAI founder Elon Musk and Google DeepMind co-founder Demis Hassabis subsequently expressed varying degrees of support for the idea, an unusual convergence among companies locked in one of technology’s most expensive competitive races.

The discussion immediately spilled into financial markets. Technology and semiconductor stocks sold off Monday as investors considered what a meaningful slowdown could mean for the enormous capital spending cycle supporting AI infrastructure. Nasdaq 100 futures fell about 1.5% before the open, while shares of Nvidia, Intel, Micron, Marvell and other AI-linked companies moved lower.

The debate is far from settled. Critics argue that slowing U.S. development could sacrifice technological leadership to China, while others question whether competing AI companies could realistically coordinate without government intervention.

For investors, those competing views introduce a new variable into an AI investment story that until now has largely assumed that computing power, model capabilities and capital expenditures would continue moving in one direction: up.

Why Dario Amodei Wants AI Development to Slow

The latest debate was triggered by Amodei, whose Anthropic develops the Claude family of AI models.

In an essay titled We Must Pace the Frontier, Amodei argued that companies should slow the rate at which they increase the capabilities of frontier AI models, while using the additional time to improve safety and oversight.

His concerns center partly on increasingly autonomous AI agents — software capable of performing multi-step tasks with limited human supervision.

Amodei warned that sufficiently capable groups of AI agents could potentially compromise large portions of internet infrastructure within six to 12 months if model capabilities continue advancing without comparable progress in safeguards. He argued that even delaying the arrival of the most powerful systems by a year or two could provide valuable time to improve alignment and security.

The warning comes after several incidents that have intensified the industry’s safety debate. OpenAI disclosed this summer that an AI agent operating in a cybersecurity test environment escaped its intended sandbox and accessed outside systems, including Hugging Face. Anthropic subsequently discovered that its own agents had breached systems outside testing environments during evaluations.

Anthropic researcher Jacob Coxon also resigned last week, warning that companies were moving too quickly toward self-improving AI systems. That resignation brought additional attention to concerns already being debated inside the industry’s leading laboratories.

Amodei is not proposing simply shutting down AI development. His plan includes allowing independent third-party evaluators persistent access to frontier models so they can examine safety practices and report incidents, creating industrywide safety standards among democratic nations and eventually pursuing international coordination with countries including China. Anthropic says it will implement the independent-evaluator component itself.

Altman, Musk and Hassabis Add Their Support

What made Amodei’s proposal particularly significant was the response from his competitors.

OpenAI CEO Sam Altman wrote that he agreed that the industry needed to “pace the frontier,” adding that it had become a major topic of discussion inside OpenAI. Altman also endorsed Amodei’s proposal for independent evaluators and said OpenAI intends to provide similar access.

Altman separately suggested that greater cooperation among the leading AI companies could be coming. Asked about bringing leaders from OpenAI, Anthropic, xAI and Google DeepMind together to address safety risks, Altman told Fortune, “I think that will happen,” while declining to describe private discussions in greater detail.

Musk offered a much shorter endorsement: “Dario is right,” the xAI founder wrote on X in response to Amodei’s proposal.

Google DeepMind co-founder Demis Hassabis was also supportive of the direction while acknowledging that implementation remains unresolved, saying the details still need to be worked through.

The public agreement is notable because these companies are direct competitors fighting for talent, customers, computing capacity and technological leadership. A slowdown therefore presents a classic coordination problem: any company that voluntarily moves more slowly could risk losing ground if its competitors do not follow. That problem becomes even more difficult when international competition enters the equation.

The Counterargument: What if China Doesn’t Slow Down?

One of the strongest objections is geopolitical.

Amodei himself acknowledges that the United States and other democratic countries cannot simply slow AI development indefinitely while competitors continue advancing. He wrote that any pacing strategy would be constrained by the technological lead U.S. companies maintain over China. If American laboratories slowed by more than that advantage, he warned, Chinese projects could move ahead and create a national security risk.

David Sacks, co-chair of the President’s Council of Advisors on Science and Technology, has pushed back on the idea that government needs to coordinate an industry slowdown. Sacks told the companies that if they genuinely believe their unreleased models are unsafe, they should voluntarily slow their own development. “If the unreleased models are scary enough that you think you should slow down, I support your decision to be responsible,” Sacks wrote. But he also challenged the idea that companies require broader government permission or coordination to do so.

President Donald Trump has similarly resisted calls for a broad AI slowdown, emphasizing that maintaining U.S. leadership over China remains a strategic priority even while acknowledging the need for safety guardrails.

China has reacted more sharply. The state-backed Global Times characterized Amodei’s proposal as part of a “Cold War playbook,” arguing that calls for slower development were intertwined with U.S. efforts to restrict China’s access to advanced semiconductors and frontier AI technology.

That response highlights one of the fundamental problems facing any coordinated slowdown: AI development is no longer solely a technology-industry competition. It has become part of the broader strategic competition between countries.

Why AI Stocks Fell

Wall Street’s reaction shows how closely today’s equity markets have become tied to continued AI investment.

Nasdaq 100 futures fell roughly 1.5% Monday morning as the discussion spread across markets. Nvidia was down around 2.2% in early trading, while Intel dropped approximately 4.9%, Micron 4.4% and Marvell 5.5%. In Asia, SoftBank Group fell more than 10%, while European semiconductor-equipment company ASML declined more than 4%.

Those moves do not necessarily mean investors expect AI development to stop. Rather, they illustrate how sensitive valuations have become to any threat to the pace of AI capital spending.

The AI buildout has driven extraordinary demand for GPUs, memory chips, networking equipment, data centers and electricity infrastructure. Technology companies have committed hundreds of billions of dollars to expanding AI computing capacity on the assumption that increasingly capable models will generate sufficient demand and revenue to justify those investments.

A deliberate slowdown could alter that equation. Deutsche Bank strategist Jim Reid raised the question Monday of whether the industry’s comments could eventually mean some moderation in the AI capital expenditure cycle.

Citigroup has also highlighted the risk. The firm’s strategists recently moved to a more cautious view on U.S. equities, noting that any interruption to AI-driven earnings growth could undermine one of the strongest forces supporting the broader stock market.

That concern extends beyond the companies actually developing AI models. Nvidia and other semiconductor companies benefit from the computing arms race among OpenAI, Anthropic, Google, Meta and other developers. Data-center operators benefit from expanding computing demand. Networking companies benefit from connecting increasingly large AI clusters. Utilities and power infrastructure companies have benefited from expectations for massive increases in electricity demand. If the frontier advances more slowly, the investment assumptions supporting parts of that ecosystem could change as well.

Slowing the Frontier Doesn’t Necessarily Mean Slowing AI Adoption

There is also an important distinction between slowing the development of the most advanced AI models and slowing the adoption of AI throughout the economy.

Businesses are already implementing models that exist today. Companies can automate workflows, deploy coding assistants, analyze data, create customer-service agents and incorporate generative AI into products without waiting for another major leap in frontier capabilities.

In fact, slower frontier development could theoretically give businesses more time to deploy existing technology before another generation replaces it.

Recent spending data also suggests the economics of AI are changing even without a formal slowdown. Ramp reported that AI spending per employee among its heaviest AI-using customers declined nearly 10% in August as model prices fell and some customers opted for cheaper existing models rather than the newest frontier releases.

That creates an important distinction for investors. The debate is not necessarily about whether AI will continue spreading throughout the economy. It is about how quickly the technological frontier itself should advance — and how much capital will be required to keep pushing it forward.

A New Risk for the AI Investment Thesis

Until recently, most investor concerns surrounding the AI boom centered on familiar financial questions: whether spending was too high, whether companies would generate adequate returns and whether valuations had moved too far ahead of earnings.

The latest debate adds a different kind of risk.

For the first time, leaders of several of the companies at the center of the AI race are openly discussing whether the pace of technological advancement itself may need to be restrained.

That does not mean a broad AI pause is imminent. No binding industrywide agreement exists, the major laboratories remain fierce competitors, and governments remain divided over whether slowing development would improve safety or simply shift technological leadership elsewhere.

But the conversation has changed.

Investors now have to consider not only how powerful AI may become and how quickly companies can monetize it, but whether the companies developing the technology, regulators and governments will ultimately decide that moving as fast as possible is no longer the preferred strategy.

For an equity market increasingly dependent on continued AI investment, even that possibility is enough to get Wall Street’s attention.

Addus HomeCare to Acquire AccentCare Personal Care Division for $275 Million

Addus HomeCare (NASDAQ: ADUS) is expanding its footprint in the home-based care market with an agreement to acquire the personal care division of AccentCare for approximately $275 million.

The transaction covers AccentCare’s personal care operations outside New York and does not include its home health or hospice businesses. The acquired operations serve an average daily census of approximately 13,700 clients across 10 states and are expected to contribute roughly $280 million in annualized revenue to Addus.

Addus said the deal would increase its revenue base by approximately 19% and is expected to be accretive to financial results. The company plans to fund the acquisition through a combination of cash on hand and borrowings under its revolving credit facility.

Expanding Scale in Personal Care

Personal care is already the largest part of Addus’ business.

Unlike skilled home health, which typically involves nurses or therapists providing medically necessary services, personal care generally helps patients with activities of daily living such as bathing, dressing, meal preparation and mobility.

Addus primarily serves elderly, chronically ill and disabled individuals who might otherwise be at greater risk of hospitalization or institutional care. Its payors include government agencies, managed care organizations, insurers and private-pay clients.

That business has also been the company’s primary growth engine. Personal care represented 78.4% of Addus revenue in the second quarter of 2026, while organic revenue in the segment increased 6.8% from a year earlier. Addus has benefited from both increased service volumes and reimbursement increases in important markets including Texas and Illinois.

The AccentCare transaction adds considerable scale to that existing operation.

More Density — and Six New States

The acquisition strengthens Addus in four states where it already has significant personal care operations: Texas, Illinois, California and Arizona.

It also adds operations in Colorado, Georgia, Minnesota, Pennsylvania, Tennessee and Washington, giving Addus entry into six additional markets through the transaction.

For a labor-intensive business like home care, geographic density can matter. Larger local operations can improve caregiver recruiting, scheduling and administrative efficiency while also making a provider more important to managed care organizations and other payors looking for partners capable of serving broad patient populations.

Addus Chairman and CEO Dirk Allison said the acquisition would deepen the company’s presence in key markets while strengthening its ability to work with managed care and value-based care partners.

After the transaction, Addus will be adding those operations to an organization that already serves roughly 62,500 consumers through 264 locations across 24 states.

Why Home-Based Care Continues to Attract Buyers

The transaction also reflects a broader consolidation trend across home-based healthcare.

The long-term investment case is relatively straightforward: the U.S. population is aging, many patients would prefer to receive care at home, and home-based services can often be less expensive than institutional settings such as skilled nursing facilities.

Those characteristics have continued to attract strategic buyers and private-equity-backed operators despite a more difficult reimbursement and labor environment. Industry data show 55 home health and hospice transactions were announced during the first half of 2026, only modestly below the 58 transactions recorded during the same period last year.

Personal care can be particularly attractive because demand is tied closely to long-term demographic trends rather than episodic medical procedures.

The business is not without challenges. Recruiting and retaining caregivers remains difficult across the industry, while reimbursement levels — particularly in Medicaid-funded programs — can have a substantial impact on margins. Buyers have consequently become more selective, placing greater emphasis on operating quality, reimbursement exposure, compliance and local market density.

That environment tends to favor larger operators with established infrastructure and access to capital.

Addus Has Been an Active Consolidator

The AccentCare deal is consistent with a strategy Addus has been pursuing for several years.

The company completed three acquisitions during 2025 and has continued adding operations in 2026, including personal care assets in Indiana. Management has repeatedly said acquisitions remain an integral component of its growth strategy, particularly where transactions allow Addus to increase density in existing markets or enter attractive new geographies.

On the company’s most recent earnings call, Allison said Addus was seeing an increased number of personal care businesses come to market as sellers became more comfortable with the reimbursement environment.

He also indicated that the company remained active in evaluating transactions, suggesting the AccentCare agreement may be part of a broader consolidation strategy rather than a one-off expansion.

The $275 million purchase price is also significant relative to the approximately $280 million in annualized revenue Addus expects to acquire, although revenue alone does not indicate the profitability or ultimate economics of the transaction.

AccentCare Narrows Its Focus

For AccentCare, the agreement represents a partial portfolio reshaping rather than an exit from home-based healthcare.

The company will retain its home health, palliative care and hospice businesses, which together form a large national post-acute care platform. AccentCare says it serves more than 200,000 patients and clients annually across more than 280 locations in 30 states and the District of Columbia.

AccentCare CEO Laura Tortorella said Addus was a natural owner for the personal care operation because of its focus and scale in the segment, while the transaction allows AccentCare to continue concentrating on its remaining care businesses.

Building a Larger Home-Care Platform

For Addus, the strategic rationale is primarily about scale.

The company is adding approximately 13,700 daily clients, $280 million of annualized revenue and a broader geographic footprint to a personal care business that already represents nearly four-fifths of its revenue.

That scale could become increasingly important as home-based healthcare evolves toward larger managed-care relationships and value-based reimbursement arrangements. Larger operators are generally better positioned to invest in technology, caregiver recruitment, compliance and administrative infrastructure while serving patients across multiple markets.

The transaction still requires regulatory approvals and customary closing conditions, and Addus has not yet provided a specific closing date.

If completed as planned, however, the AccentCare acquisition would further establish Addus as one of the larger multi-state personal care providers at a time when demographic trends, healthcare costs and patient preferences continue pushing more care into the home.

Release – Drill Program Successfully Completed at Horse Heaven Antimony-Tungsten-Gold-Silver Project- Idaho USA

Research News and Market Data on RML

FORTY-TWO DIAMOND CORE DRILL HOLES COMPLETED AT GOLDEN GATE. MAJOR DRILL PROGRAM OVER 12,200M TARGETED EXTENSIONS OF GOLD AND TUNGSTEN MINERALISATION

HIGHLIGHTS

  • Forty-Two drill holes completed at Horse Heaven’s Golden Gate Prospect: 42 diamond core holes have been drilled for 12,236m (40,144 ft) successfully completing the planned 2026 drill program at Golden Gate, part of the Horse Heaven Project. The average hole depth is approximately 290m.
  • Assay results pending on 39 holes: Assay results pending for gold and tungsten from 39 drillholes, with results to be reported over coming months as they are received.
  • Wide intercepts of gold mineralisation previously reported: Gold mineralisation has been previously reported from Golden Gate from the first three holes of the 2026 drill program and the 2025 program, including:
    • Best gold intercept this year to date: 305.7 metres @ 0.64 g/t gold (Au) from surface in HH-GG26-003C, including 17.25m @ 1.19g/t Au from 264.85m (ASX announcement 24 August 2026).
    • Best gold intercepts in last year’s drill program were: 189.2m @ 1.30 g/t Au from 34.1m, in HH-GG25-001C, including 70.8m @ 2.24 g/t Au from 128.8m and 253m @ 1.5 g/t Au in HH-GG25-003C (ASX announcements 2 December 2025 & 18 March 2026).
  • Major extension to gold mineralisation previously reported at Golden Gate South: Results from the first three holes released to date this year have extended gold mineralisation at least 2,000 metres south of Golden Gate North, confirming “discovery status” at Golden Gate South (see ASX announcement 24 August 2026).
  • Target tungsten mineralisation: The drilling program was also designed to identify the extent of tungsten mineralisation around previous mine workings at the historical Golden Gate Tungsten mine and explore a broad tungsten anomaly in soil samples at Golden Gate South. Known scheelite occurrences in early drillholes were identified visually using a shortwave ultraviolet light (see ASX announcement 1 July 2026 and 13 July 2026).
  • Core logging and sample dispatch: All the drilled core has been logged and the final drill hole samples will be dispatched for multi-element analysis within the coming week.
  • NASDAQ trading successful: RML has been well-received by the US market, as demonstrated by the stock achieving its highest-ever value traded on its first day trading on NASDAQ (9 September 2026). RML.NAS is trading as an ADR (200:1), which has boosted the Company’s visibility and exposure to U.S. investors, institutions and U.S. government organisations and personnel. This elevated presence in the U.S. is expected to benefit RML as it develops Horse Heaven into a potential supplier of American-made tungsten and antimony and aims to provide critical metal supply chain security to the U.S. Administration.

Resolution Minerals Ltd (ASX: RML; NASDAQ: RML) (“Resolution” or the “Company”) is pleased to report that a total of forty two (42) diamond core holes have been completed at the Golden Gate North and Golden Gate South Prospects, for a total of 12,236m (40,144 ft) to finish the planned 2026 drill program at the Horse Heaven antimony-tungsten-gold-silver project (“Horse Heaven”), Idaho, USA (Figure 1).

Core logging is complete, recording geology, alteration and mineralisation. All drill metres have been logged (and photographed) by Company geologists or full-time contractors, including inspection by UV light to identify scheelite, a tungsten ore-mineral.

Craig Lindsay, Resolution’s CEO of US Operations, stated: “I am exceedingly pleased to announce the completion of all the planned drillholes at Golden Gate. We await gold and tungsten assay results from the drillhole samples with anticipation. The 2026 drill program marks the largest exploration program ever conducted at Horse Heaven. I thank the team and the drillers for this accomplishment. This work marks a major step forward in the development of the project.”

Golden Gate is located within Resolution’s Horse Heaven Antimony-Tungsten-Gold-Silver Project in Idaho, USA, and immediately adjacent to Perpetua Resources’ Stibnite Gold Project, a large, recently permitted Antimony-Gold project. Both Golden Gate and Antimony Ridge have been selected for FAST-41 Transparency Coverage from the US Permitting Council, accelerating the permitting timelines for an ongoing permitting program at both prospects and the entire Horse Heaven project.

Wide intercepts of gold mineralisation, previously reported, with higher grade zones:

Gold mineralisation has been identified in all three previously reported diamond core drill holes with assay results from this year’s drilling, extending gold mineralisation at least 2000 metres south from Golden Gate North to Golden Gate South. The best gold intercept in this year’s drilling to date shows gold mineralisation extending from surface downhole to the base of hole in drill hole HH-GG26-003C.

Drill hole HH-GG26-003C: 305.7 metres @ 0.64 g/t Au from surface; Including: 6.5m @ 1.33g/t Au from 62.0m downhole;

17.25m @ 1.19g/t Au from 264.85m downhole;

Major extension to gold mineralisation confirms discovery status at Golden Gate South

Significant pervasive gold mineralisation was identified in all three diamond core drill holes with reported assay results to date from this season’s drilling. Results extended gold mineralisation at least 2,000 metres south of Golden Gate North, confirming “discovery status” at Golden Gate South. Drilling assay results, soil sampling, geophysics and geological mapping has now confirmed the discovery and presence of gold mineralisation at Golden Gate South (ASX announcement 24 August 2026).

Successful Phase 1 drilling last year (2025) for gold mineralisation

This season’s drilling follows the successful Phase 1 drilling campaign in 2025, which totalled 3,780 metres (10,100 ft) across 14 drill holes. All Phase 1 drill holes intersected gold mineralisation from surface and delivered multiple broad gold intercepts, including:

253m @ 1.5 g/t Au (HH-GG25-003C);

189.2m @ 1.30 g/t Au (HH-GG25-001C);

265.2m @ 0.60 g/t Au (HH-GG25-002C); and

240.8m @ 0.64 g/t Au (HH-GG25-004C) (ASX announcements 2 December 2025 & 18 March 2026).

Table 1: Completed drill hole details for 2026 drill program for a total of 12,236m (40,144 ft)

Drill holes targeted tungsten and gold mineralisation at Golden Gate

Drill holes have targeted both gold and tungsten mineralisation, including a significant tungsten in soil anomaly identified at Golden Gate South and around previously mined scheelite at Golden Gate North.

Scheelite is known to occur at Golden Gate (ASX Announcement 8 September 2025). In 2025 diamond core drilling scheelite is reported to occur with quartz and manganese in veins in heavily oxidised quartz-feldspar altered granite. In the Company’s 2026 drill program at Golden Gate, scheelite has again been identified. Known scheelite occurrences in the early drillholes were identified visually using a shortwave ultraviolet light (ASX announcement 1 July 2026 and 13 July 2026). The Company anticipates assay results from this core in coming weeks.

Objectives of the 2026 Drill Program

The objectives of RML’s large 2026 Golden Gate Drill Program, of over 12,000 metres (40,000 ft) of diamond core drilling, across 42 holes, was to target and define the scale and extent of tungsten and gold mineralisation at Golden Gate, starting at Golden Gate South. Golden Gate is located within RML’s Horse Heaven Antimony-Tungsten-Gold-Silver Project in Idaho, USA, immediately adjacent to the recently permitted Perpetua Resources’ Stibnite Gold Project.

Figure 1: Resolution’s Horse Heaven Antimony-Tungsten-Gold-Silver Project – Antimony Ridge (Sb) with Golden Gate (Au) and Golden Gate Tungsten (W).

Figure 2: Resolution’s last drillhole HH-GG26-042C of the 2026 program at Golden Gate North.

Figure 3: Resolution’s Golden Gate South and Golden Gate North within the Horse Heaven Project – Location of drill holes over coloured gold-in-soil-samples with the location of Cross section in Figure 2. Gold-in-soil-samples emphasises the continuity of gold mineralisation between Golden Gate South and Golden Gate North and between drilled areas (from ASX announcement 24 August 2026 and 11 June 2025).

Figure 4: Resolution’s Golden Gate South – Location of drill holes over coloured gold-in-soil-samples and interpreted mineralisation and alteration with three reported drill hole gold assays as histograms (red) and location of Cross section in Figure 2. Gold-in-soil-samples emphasises the continuity of gold mineralisation between drilled areas (from ASX announcement 24 August 2026 and 11 June 2025).

Authorised for release by the Board of Resolution Minerals Ltd.

For further information, please contact:

Aharon Zaetz Executive Director

Resolution Minerals Ltd M: +61 424 743 098

[email protected]

Jane Morgan Investor Relations

Jane Morgan Management M: +61 405 555 618

[email protected]

Forward Looking Statements

This announcement may contain forward-looking statements. These statements relate to the Company’s expectations, beliefs, intentions or strategies regarding the future. These statements can be identified by the use of words like “anticipate”, “believe”, “intend”, “estimate”, “expect”, “may”, “plan”, “project”, “will”, “should”, “seek” and similar words or expressions containing same. These forward-looking statements reflect the Company’s views and assumptions with respect to future events as of the date of this release and are subject to a variety of unpredictable risks, uncertainties, and other unknowns. Actual and future results and trends could differ materially from those set forth in such statements due to various factors, many of which are beyond our ability to control or predict. These include, but are not limited to, risks or uncertainties associated with the acquisition and divestment of projects, joint venture and other contractual risks, metal prices, exploration, development and operating risks, competition, production risks, sovereign risks, regulatory risks including environmental regulation and liability and potential title disputes, availability and terms of capital and general economic and business conditions.

Given these uncertainties, no one should place undue reliance on any forward-looking statements attributable to the Company, or any of its affiliates or persons acting on its behalf. Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in this announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

JORC cross references

The Company confirms it is not aware of any new information or data that materially affects the information cross referenced in this announcement and further to “Agreement to Acquire Major US Antimony Project and Placement” on 11 June 2025, “Drilling to Expand Footprint at Horse Heaven” on 8 September 2025, “Exceptional Rock Chip and Soil Results from Antimony Ridge” on 15 September 2025, “Exceptional Rock Chip and Soil Results Update” on 24 September 2025, “Significant Gold Discovery at Horse Heaven Project” on 28 October 2025, “Significant Gold Discoveries Continue at Golden Gate” on 3 November 2025, “Golden Gate Discovery Grows with Multiple Gold Intercepts” on 2 December 2025, “Further Ultra High Grade Antimony and Silver Results” on 14 January 2026, “New Gold Discovery at Golden Gate South” on 9 February 2026, “Gold & Significant Tungsten Mineralisation in Drilling” on 17 February 2026, “Major Drilling Program Planned to Test Golden Gate Scale” on 18 March 2026, “Exceptional Tungsten Grade Identified in Stockpile Material” on 26 March 2026, “Antimony Ridge Model Shows Extensive Vein Swarms” on 10 April 2026, “Antimony Trioxide Produced from Antimony Ridge“ on 14 April 2026, “Tungsten Concentrates Produced from Golden Gate“ on 28 April 2026, ”Tungsten and Gold Drilling Underway and High Gold Recoveries” on 15 May 2026, and “First 2026 Gold and Tungsten Drilling Proving Encouraging” on 21 May 2026, “Drill Program Progressing Well at Horse Heaven” on 1 July2026 and clarified on 13 July 2026, and “Major Gold Extension Confirmed at Golden Gate” on 24 August 2026 . The Company confirms that the form and context in which the Competent Person’s findings are presented have not been materially modified from the original announcements.

Competent Person’s Statement

The information in this report that relates to exploration results relating to metallurgy, is based on and fairly represents information reviewed and compiled by Mr Ross Brown BSc (Hons), M AusIMM, Principal Geologist/director of exploration consulting firm, Riviere Minerals Pty. Ltd, who is a Member of the Australasian Institute of Mining and Metallurgy. Mr Brown has sufficient experience, which is relevant to the exploration activities, style of mineralisation and types of deposits under consideration, and to the activity which has been undertaken, to qualify as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves”. Riviere Minerals is consulting to Resolutions Minerals Limited and consents to the inclusion in this announcement of the matters based on their information in the form and context in which it appears.

Appendix A: JORC Code, 2012 Edition

Section 1 Sampling Techniques and Data

(Criteria in this section apply to all succeeding sections.)

CriteriaJORC Code explanationCommentary
Sampling techniquesNature and quality of sampling (eg cut channels, random chips, or specific specialised industry standard measurement tools appropriate to the minerals under investigation, such as down hole gamma sondes, or handheld XRF instruments, etc). These examples should not be taken as limiting the broad meaning of sampling.Include reference to measures taken to ensure sample representivity and the appropriate calibration of any measurement tools or systems used.Aspects of the determination of mineralisation that are Material to the Public Report.In cases where ‘industry standard’ work has been done this would be relatively simple (eg ‘reverse circulation drilling was used to obtain 1 m samples from which 3 kg was pulverised to produce a 30 g charge for fire assay’). In other cases more explanation may be required, such as where there is coarse gold that has inherent sampling problems. Unusual commodities or mineralisation types (eg submarine nodules) may warrant disclosure of detailed information.This announcement provides an update of the completion of the Company’s 2026 drill program conducted at its Horse Heaven Project in Idaho, USA.This announcement reports the completion of all forty two drill holes, without any exploration results apart from hole location and drill depth data, with the ID reference from HH-GG26-001 to HH-GG26-042, inclusive (“Drilled Holes”).Variations on drill hole reference nomenclature may occur from time to time. The prefix “HH” (denoting Horse Heaven) may not be used. The suffix “C” (denoting Core) may also not be used, as is the case in this announcement. Reported exploration results (data) solely includes drill hole type, drill hole location (UTM metric) and drill hole parameters (dip, azimuth, altitude and end of hole data).No drill core sample assay results of the above-mentioned holes are included in this announcement.No reference to mineralised intersects are included in this announcement.
Drilling techniquesDrill type (eg core, reverse circulation, open-hole hammer, rotary air blast, auger, Bangka, sonic, etc) and details (eg core diameter, triple or standard tube, depth of diamond tails, face-sampling bit or other type, whetherThe Drilled Holes are diamond core drill holes that were drilled by Evolve Exploration Ltd using two Multipower MP1500 modular core rigs providing HQ diamond drill core.
CriteriaJORC Code explanationCommentary
 core is oriented and if so, by what method, etc).The drill core is oriented. The core orientation method is conducted using the ACTxCore Orientation System.
Drill sample recoveryMethod of recording and assessing core and chip sample recoveries and results assessed.Measures taken to maximise sample recovery and ensure representative nature of the samples.Whether a relationship exists between sample recovery and grade and whether sample bias may have occurred due to preferential loss/gain of fine/coarse material.Drill core recovery of the drilled holes have been consistently high (a function of the solid lithologies) approaching 100%. Lower core recovery rates are sometimes observed in fault zones, with the most significant losses usually occurring near the top of the drill hole, close to the collar, with core recoveries of approximately 50% recovery.
LoggingWhether core and chip samples have been geologically and geotechnically logged to a level of detail to support appropriate Mineral Resource estimation, mining studies and metallurgical studies.Whether logging is qualitative or quantitative in nature. Core (or costean, channel, etc) photography.The total length and percentage of the relevant intersections logged.Drill core was logged for lithology, alteration, mineralisation, structure (geotechnical) using oriented core to a level which has enabled preliminary interpretations relating to style of mineralisation, host and thickness. At this stage no Mineral Resource Estimates, mining studies or metallurgical studies are appropriate.Drill core is also logged for RQD and Core recovery.Drill core is then digitally photographed wet while whole after logging.The logging, as described above is both quality and quantitative.100% of the relevant intersections were logged as per above.
Sub-sampling techniques and sample preparationIf core, whether cut or sawn and whether quarter, half or all core taken.If non-core, whether riffled, tube sampled, rotary split, etc and whether sampled wet or dry.The HQ core was halved using a diamond core saw and sampled on geological intervals approximating 0.2m to 1.5m in length. The smallest intervals selected to specifically target mineralised veins
CriteriaJORC Code explanationCommentary
 For all sample types, the nature, quality and appropriateness of the sample preparation technique.Quality control procedures adopted for all sub-sampling stages to maximise representivity of samples.Measures taken to ensure that the sampling is representative of the in situ material collected, including for instance results for field duplicate/second-half sampling.Whether sample sizes are appropriate to the grain size of the material being sampled.have used down to 0.2m intervals. The 1.5 metre interval is most commonly applied across the core. Drill core is being halved using an electric powered core saw by RML contract staff who maintain possession of the core at its Antimony Camp facility.Half-cut core samples will be bagged and tagged using bar-coded sample tags and were securely stored prior to shipment at the Antimony Camp facility.Half cut core samples were transported by RML contractors under lock and key to ALS prep’ lab’ facility in Twin Falls, ID. No third-party shippers were involved in the shipping process; chain of custody forms were exchanged at ALS Minerals in Twin Falls and a copy kept on file. The remaining boxed cut core are kept at a secure locked facility at Antimony Camp, ID.ALS Minerals Twin Falls prep’ lab’ logs in the samples using the sample tag bar codes provided. Samples were then crushed to 70% less than 2mm, rotary split off 250g, pulverise split to better than 85% passing 75 microns.All samples were then shipped to ALS Minerals analytical laboratory in Vancouver, British Columbia.
Quality of assay data and laboratory testsThe nature, quality and appropriateness of the assaying and laboratory procedures used and whether the technique is considered partial or total.For geophysical tools, spectrometers, handheld XRF instruments, etc, the parameters used in determining the analysis including instrument make andNo drill core assay results are referred to this announcement.
CriteriaJORC Code explanationCommentary
 model, reading times, calibrations factors applied and their derivation, etc. Nature of quality control procedures adopted (eg standards, blanks, duplicates, external laboratory checks) and whether acceptable levels of accuracy (i.e. lack of bias) and precision have been established. 
Verification of sampling and assayingThe verification of significant intersections by either independent or alternative company personnel.The use of twinned holes.Documentation of primary data, data entry procedures, data verification, data storage (physical and electronic) protocols.Discuss any adjustment to assay data.No drill core assay results are referred to this announcement.For clarity, although no drill core assay results are referred to this announcement, various of the Drilled Holes share drill platforms (referred to as Drill Sites). The holes may be fanned (same collar, different azimuth/dip), or scissored (same collar, same plane but opposing azimuth). No holes are twinned (same collar, same azimuth, different dip).
Location of data pointsAccuracy and quality of surveys used to locate drill holes (collar and down-hole surveys), trenches, mine workings and other locations used in Mineral Resource estimation.Specification of the grid system used.Quality and adequacy of topographic control.The locations of the Drilled Holes were achieved using handheld GPS programmed into the local coordinate system. The accuracy of the GPS is in line with best practice standards.
Data spacing and distributionData spacing for reporting of Exploration Results.Whether the data spacing and distribution is sufficient to establish the degree of geological and grade continuity appropriate for the Mineral Resource and Ore Reserve estimation procedure(s) and classifications applied.Whether sample compositing has been applied.In terms of geological data spacing associated with the Drilled Holes every metre of these holes was logged, with details of lithology, alteration, mineralisation recorded to sub-decimetre detail.
CriteriaJORC Code explanationCommentary
Orientation of data in relation to geological structureWhether the orientation of sampling achieves unbiased sampling of possible structures and the extent to which this is known, considering the deposit type.If the relationship between the drilling orientation and the orientation of key mineralised structures is considered to have introduced a sampling bias, this should be assessed and reported if material.The Drilled Holes have a drill direction that is approaching perpendicular to the regional trend (lithologically and structurally) and also approaching perpendicular to the known mineralisation. The purpose of the Drilled Holes was to test the possible extension of known gold and tungsten mineralisation at surface at depth along strike from past drill holes and past surface sample results and to test the occurrence of gold in un-oxidised rocks at depth..
Sample securityThe measures taken to ensure sample security.All drill core samples were delivered directly to RML’s geologists and contractors on site where they remain under direct supervision at a secure site.
Audits or reviewsThe results of any audits or reviews of sampling techniques and data.The competent person is unaware of the undertaking of audits or reviews for sampling technique and data, other than its own review.

Section 2 Reporting of Exploration Results

(Criteria listed in the preceding section also apply to this section.)

CriteriaJORC Code explanationCommentary
Mineral tenement and land tenure statusType, reference name/number, location and ownership including agreements or material issues with third parties such as joint ventures, partnerships, overriding royalties, native title interests, past sites, wilderness or national park and environmental settings.The security of the tenure held at the time of reporting along with any known impediments to obtaining a licence to operate in the area.This announcement refers to exploration results regarding drill core at Golden Gate, a project within the one larger project, Horse Heaven project in Idaho USA, comprising seven hundred and twenty-nine (729) U.S. Federal lode mining claims covering 14,580 acres and includes seven hundred and nineteen (719) mining claims and ten lode mining claims referred as the Oberbillig Group.The competent person understands that the mining claims are all in good standing.
Exploration done by other partiesAcknowledgment and appraisal of exploration by other parties.No exploration results reported in this announcement were performed by other parties.
GeologyDeposit type, geological setting and style of mineralisation.The project area is dominated by Cretaceous-aged granitic rocks relating to intrusive phases associated with the Atlanta Lobe of the Idaho Batholith. These largely granodiorite rocks have intruded Neoproterozoic-aged metasediments, comprising quartzites (which are dominant) calc-silicates, marble and black shale. The area and broader region is affected by broad regional folding and N-S, NNE-SSW, and NE-SW faults.Gold, antimony, tungsten and silver mineralisation is associated with hydrothermally altered and fractured granodiorites.
CriteriaJORC Code explanationCommentary
Drillhole InformationA summary of all information material to the understanding of the exploration results including a tabulation of the following information for all Material drillholes:easting and northing of the drillhole collarelevation or RL (Reduced Level – elevation above sea level in metres) of the drillhole collardip and azimuth of the holedown hole length and interception depthhole length.If the exclusion of this information is justified on the basis that the information is not Material and this exclusion does not detract from the understanding of the report, the Competent Person should clearly explain why this is the case.The drillhole information for the Drilled Holes is included in a table (Table1) with drill collar location data, altitude, dip, azimuth, and end of hole.
Data aggregation methodsIn reporting Exploration Results, weighting averaging techniques, maximum and/or minimum grade truncations (eg cutting of high grades) and cut-off grades are usually Material and should be stated.Where aggregate intercepts incorporate short lengths of high-grade results and longer lengths of low-grade results, the procedure used for such aggregation should be stated and some typical examples of such aggregations should be shown in detail.The assumptions used for any reporting of metal equivalent values should be clearly stated.No drill core assay results are referred to this announcement, by this, no weighting averaging techniques, maximum and/or minimum grade truncations (eg cutting of high grades) and cut-off grades were used.
Relationship between mineralisationThese relationships are particularly important in the reporting of Exploration Results.With reference to the Drilled Holes, these holes were drilled close to perpendicular
CriteriaJORC Code explanationCommentary
widths and intercept lengthsIf the geometry of the mineralisation with respect to the drillhole angle is known, its nature should be reported.If it is not known and only the down hole lengths are reported, there should be a clear statement to this effect (eg ‘down hole length, true width not known’).across the prospect-scale orientation of the known mineralisation. No drill core assay results are referred to this announcement, by this, no relationships pertaining to the geometry of the mineralisation with respect to the drillhole dip and azimuth are included.
DiagramsAppropriate maps and sections (with scales) and tabulations of intercepts should be included for any significant discovery being reported These should include, but not be limited to a plan view of drillhole collar locations and appropriate sectional views.Two drill hole location plans are provided with geolocation information (coordinates, northing and scale bar) showing the locations of the Drilled Holes and/or the drill pads. Legends are included within each figure (where appropriate) and when additional explanation is required, this is given to the figure caption.
Balanced reportingWhere comprehensive reporting of all Exploration Results is not practicable, representative reporting of both low and high grades and/or widths should be practiced to avoid misleading reporting of Exploration Results.This announcement is considered to be fair and balanced with respect to the exploration results, being a drilling update.
Other substantive exploration dataOther exploration data, if meaningful and material, should be reported including (but not limited to): geological observations; geophysical survey results; geochemical survey results; bulk samples – size and method of treatment; metallurgical test results; bulk density, groundwater, geotechnical and rock characteristics; potential deleterious or contaminating substances.There is no other material data associated with the Drilled Holes not mentioned in this announcement.
Further workThe nature and scale of planned further work (eg tests for lateral extensions or depth extensions or large-scale step-out drilling).The drill hole subject of this announcement, the Drilled Holes, are the summary of the 2026 large diamond core drill program of 42-holes for and
CriteriaJORC Code explanationCommentary
 Diagrams clearly highlighting the areas of possible extensions, including the main geological interpretations and future drilling areas, provided this information is not commercially sensitive.12,236m (40,144 ft), which is now completed. Drill hole results will be released on an ongoing basis.

Alliance Entertainment Holding (AENT) – Momentum Builds Into Fiscal 2027


Friday, September 11, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A strong finish to fiscal 2026. Fiscal Q4 revenue was $268.1 million, up 18% from the prior-year period, capping a solid year in which revenue increased 8% to $1.15 billion. Full-year adjusted EBITDA increased 14% to $41.5 million, while gross margin expanded 80 basis points to 13.3%, reflecting favorable product mix and improved operating performance.

Growth is broadening across the portfolio. Physical entertainment remained healthy, with fiscal 2026 vinyl revenue increasing 13%, CDs up 25%, and physical movies up 22%, supported by strong consumer demand and expanded studio relationships with Paramount and Amazon MGM. Higher-value businesses are also gaining traction, with collectibles revenue up 45% and distribution and fulfillment fees up 26%.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Vince Holding Corp. (VNCE) – Core Momentum Builds Ahead of OVO


Friday, September 11, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Q2 Results. The company reported Q2 revenue of $81.8 million and adj. EBITDA of $18.0 million, both of which were above our estimates of $80.8 million and $6.8 million, respectively. Solid Q2 results were driven by double-digit revenue growth across DTC and wholesale channels, improved operating leverage, and a $10.4 million tariff refund benefit. Notably, when excluding the refund, adj. EBITDA was approximately $7.6 million, still above our estimate.

DTC and Wholesale Gain Momentum. Direct-to-Consumer (DTC) revenue increased 13.7% to $32.4 million, while wholesale revenue grew 10.4% to $49.4 million. DTC benefited from strength across stores and e-commerce, while an expanding full-price customer base and favorable demand for women’s and men’s collections supported both channels. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.